BMS Partners with BioArctic in $1.35 Billion Deal for Preclinical Alzheimer's Antibodies
Bristol Myers Squibb (BMS) has finalized a $100 million upfront payment to BioArctic, securing global rights to two preclinical Alzheimer's antibodies, BAN1503 and BAN2803[1][3]. This agreement is part of a larger deal with potential milestone payments that could reach $1.25 billion, dependent on the development and commercial success of these candidates[2][3]. BAN2803, one of the antibodies, features BioArctic's BrainTransporter technology designed to improve drug delivery across the blood-brain barrier, a significant step towards targeting Alzheimer's disease more effectively[1][2].
References
- BMS Taps Eisai’s Alzheimer’s Partner in Massive $1.35B Biobucks Deal
- BMS pays Leqembi originator $100M for next-gen preclinical Alzheimer’s prospects
- <a href="https://www.fiercebiotech.com/biotech/bristol-myers-pays-leqembi-originator-100m-next-gen-preclinical-alzheimers-prospects" hreflang="en">BMS pays Leqembi originator $100M for next-gen preclinical Alzheimer's prospects</a>
Explore Further
What specific challenges does BioArctic's BrainTransporter technology address in Alzheimer’s treatment that existing therapies do not?
How does the targeting of pyroglutamate-amyloid-beta by BAN1503 and BAN2803 differ from other approaches in Alzheimer's research?
What are the potential implications of the $1.25 billion milestone payments for BMS and BioArctic if these Alzheimer's antibodies succeed in regulatory and commercial benchmarks?
In what ways might Bristol Myers Squibb's collaboration with BioArctic influence its strategic positioning in the competitive Alzheimer's therapeutics market?
What is the significance of the $100 million upfront payment in the context of global pharmaceutical partnerships focused on preclinical compounds?